Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.
The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.
Oncology pharmacists have a challenging job caring for cancer patients.
This peer-reviewed article will show you what you need to know about the latest breakthroughs and treatment options.
Why it’s vital for pharmacists to learn about this emerging field.
The National Institutes of Health, FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
Dolutegravir, a new, once-daily option, may allow improved personalization of a patient’s medication regimen.
A small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.
CSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.